Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VYNE Therapeutics Inc. (MNLO)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 69.3% | 70.9% | 59.1% | 12.5% | 13.1% | 10.6% | 10.0% | 10.8% |
| Gross profit | 30.7% | 29.1% | 40.9% | 87.5% | 86.9% | 89.4% | 90.0% | 89.2% |
| Selling, general and administrative | 3470.5% | 3821.6% | | 2348.3% | 2605.6% | 2159.7% | | 675.7% |
| Research and development | 4862.9% | 4187.7% | 3854.3% | 2477.2% | 2648.0% | 2245.8% | 2099.2% | 466.4% |
| General and administrative | | | 778.0% | | | | 515.0% | |
| EBITDA | -8298.8% | -7973.1% | -7233.8% | -4703.9% | -5151.3% | -4301.8% | -4177.9% | -1091.9% |
| Depreciation | | | 15.1% | 34.0% | 15.5% | 14.3% | 11.7% | 3.4% |
| EBIT | -8302.7% | -7980.2% | -7248.8% | -4737.9% | -5166.8% | -4316.2% | -4189.6% | -1095.4% |
| Pre-tax income | -8022.9% | -7751.3% | -7113.6% | -4704.8% | -5637.3% | -4832.2% | -4796.7% | -256.0% |
| Income taxes | 3.2% | 3.3% | 2.7% | -60.2% | -63.1% | -51.0% | -48.1% | 0.0% |
| Net income | -8603.7% | -8400.8% | -4856.4% | -3338.0% | -5163.5% | -5473.2% | -7876.4% | -780.3% |
|